Professional Documents
Culture Documents
Diabetes 2015. Tratamiento
Diabetes 2015. Tratamiento
7. Approaches to Glycemic
Treatment
S41
POSITION STATEMENT
Most people with type 1 diabetes should be treated with multiple-dose insulin
(MDI) injections (three to four injections per day of basal and prandial insulin)
or continuous subcutaneous insulin infusion (CSII). A
Most people with type 1 diabetes should be educated in how to match prandial insulin dose to carbohydrate intake, premeal blood glucose, and anticipated activity. E
Most people with type 1 diabetes should use insulin analogs to reduce hypoglycemia risk. A
Insulin Therapy
There are excellent reviews to guide the initiation and management of insulin
therapy to achieve desired glycemic goals (1,2,3). Although most studies of MDI
versus pump therapy have been small and of short duration, a systematic review and
meta-analysis concluded that there were no systematic differences in A1C or severe
hypoglycemia rates in children and adults between the two forms of intensive insulin therapy (4). A large randomized trial in type 1 diabetic patients with nocturnal
hypoglycemia reported that sensor-augmented insulin pump therapy with the
threshold suspend feature reduced nocturnal hypoglycemia, without increasing
glycated hemoglobin values (5). Overall, intensive management through pump
therapy/continuous glucose monitoring and active patient/family participation
should be strongly encouraged (68). For selected individuals who have mastered
carbohydrate counting, education on the impact of protein and fat on glycemic
excursions can be incorporated into diabetes management (9).
The Diabetes Control and Complications Trial (DCCT) clearly showed that intensive
insulin therapy (three or more injections per day of insulin) or CSII (insulin pump therapy)
was a key part of improved glycemia and better outcomes (10,11). The study was carried
out with short- and intermediate-acting human insulins. Despite better microvascular
outcomes, intensive insulin therapy was associated with a high rate of severe hypoglycemia (62 episodes per 100 patient-years of therapy). Since the DCCT, a number of rapidacting and long-acting insulin analogs have been developed. These analogs are associated
with less hypoglycemia in type 1 diabetes, while matching the A1C lowering of human
insulins (1,12).
Recommended therapy for type 1 diabetes consists of the following:
1. Use MDI injections (three to four injections per day of basal and prandial insulin)
or CSII therapy.
2. Match prandial insulin to carbohydrate intake, premeal blood glucose, and anticipated physical activity.
3. For most patients (especially those at an elevated risk of hypoglycemia), use
insulin analogs.
4. For patients with frequent nocturnal hypoglycemia and/or hypoglycemia unawareness,
a sensor-augmented low glucose threshold suspend pump may be considered.
Pramlintide
S42
Position Statement
Investigational Agents
Metformin
Many patients with type 2 diabetes eventually require and benet from insulin
therapy. Providers may wish to consider
regimen exibility when devising a plan
for the initiation and adjustment of insulin therapy in people with type 2 diabetes
(Fig. 7.2). The progressive nature of type
2 diabetes and its therapies should be
regularly and objectively explained to patients. Providers should avoid using insulin as a threat or describing it as a failure
care.diabetesjournals.org
Position Statement
Figure 7.1Antihyperglycemic therapy in type 2 diabetes: general recommendations (15). The order in the chart was determined by historical
availability and the route of administration, with injectables to the right; it is not meant to denote any specic preference. Potential sequences of
antihyperglycemic therapy for patients with type 2 diabetes are displayed, with the usual transition moving vertically from top to bottom (although
horizontal movement within therapy stages is also possible, depending on the circumstances). DPP-4-i, DPP-4 inhibitor; fxs, fractures; GI, gastrointestinal; GLP-1-RA, GLP-1 receptor agonist; GU, genitourinary; HF, heart failure; Hypo, hypoglycemia; SGLT2-i, SGLT2 inhibitor; SU, sulfonylurea;
TZD, thiazolidinedione. *See ref. 15 for description of efcacy categorization. Consider starting at this stage when A1C is $9%. Consider starting at
this stage when blood glucose is $300350 mg/dL (16.719.4 mmol/L) and/or A1C is $1012%, especially if symptomatic or catabolic features are
present, in which case basal insulin 1 mealtime insulin is the preferred initial regimen. Usually a basal insulin (NPH, glargine, detemir, degludec).
Adapted with permission from Inzucchi et al. (15).
S43
Inhibits intestinal
a-glucosidase
2nd Generation
c Glyburide/glibenclamide
c Glipizide
c Gliclazide
c Glimepiride
c Repaglinide
c Nateglinide
c Pioglitazone
c Rosiglitazone
c Acarbose
c Miglitol
Sitagliptin
Vildagliptin
Saxagliptin
Linagliptin
Alogliptin
c
c
c
c
c
c Colesevelam
Sulfonylureas
Meglitinides
(glinides)
TZDs
a-Glucosidase
inhibitors
DPP-4 inhibitors
Bile acid
sequestrants
Activates AMP-kinase
(? other)
c Metformin
Biguanides
production
c ? Incretin levels
c ? Hepatic glucose
(glucose-dependent)
c Glucagon secretion
(glucose-dependent)
c Insulin secretion
c No hypoglycemia
c LDL-C
c No hypoglycemia
c Well tolerated
c Nonsystemic
(STOP-NIDDM)
c ? CVD events
excursions
c No hypoglycemia
c Postprandial glucose
No hypoglycemia
Durability
HDL-C
Triglycerides
(pioglitazone)
c ? CVD events
(PROactive,
pioglitazone)
c
c
c
c
c Weight
c ? Blunts myocardial ischemic
High
High
Moderate
Low
Moderate
Low
Low
Continued on p. S45
immune-mediated dermatological
effects
c ? Acute pancreatitis
c ? Heart failure hospitalizations
(atulence, diarrhea)
Weight
Edema/heart failure
Bone fractures
LDL-C (rosiglitazone)
c ? MI (meta-analyses, rosiglitazone)
c
c
c
c
preconditioning
c Hypoglycemia
excursions
c Dosing exibility
c Low durability
preconditioning
c Hypoglycemia
c Weight
c ? Blunts myocardial ischemic
c Postprandial glucose
(UKPDS)
c Extensive experience
c Microvascular risk
abdominal cramping)
c Lactic acidosis risk (rare)
c Vitamin B12 deciency
c Multiple contraindications: CKD,
acidosis, hypoxia, dehydration, etc.
Position Statement
digestion/absorption
c Insulin sensitivity
c Insulin secretion
c Insulin secretion
Table 7.1Properties of available glucose-lowering agents in the U.S. and Europe that may guide individualized treatment choices in patients with type 2 diabetes (15)
Class
Compound(s)
Cellular mechanism(s)
Primary physiological action(s)
Advantages
Disadvantages
Cost*
S44
Diabetes Care Volume 38, Supplement 1, January 2015
c
c
c
c
c
c
c Pramlintide
c Rapid-acting analogs
GLP-1 receptor
agonists
Amylin mimetics
Insulins
Advantages
Disadvantages
vomiting/diarrhea)
c Heart rate
excursions
c ? Acute pancreatitis
c Some cardiovascular c C-cell hyperplasia/medullary thyroid
risk factors
tumors in animals
c Injectable
c Training requirements
c Postprandial glucose
c Glucagon secretion
c Slows gastric emptying
c Satiety
c Injectable
c Frequent dosing schedule
c Training requirements
simultaneously reduced
vomiting)
c Glucose disposal
c Nearly universal
c Hypoglycemia
c Hepatic glucose production
c Weight gain
response
c Other
c Theoretically unlimited c ? Mitogenic effects
efcacy
c Injectable
c Microvascular risk
c Patient reluctance
(UKPDS)
c Training requirements
excursions
c Weight
c No hypoglycemia
c Weight
c Postprandial glucose
dependent)
c Glucagon secretion
(glucose-dependent)
c Slows gastric emptying
c Satiety
c LDL-C
c Creatinine (transient)
dizziness
c Genitourinary infections
c Polyuria
c Volume depletion/hypotension/
No hypoglycemia
Weight
Blood pressure
Effective at all stages
of T2DM
c
c
c
c
c
c
c
c
c
c No hypoglycemia
c ? CVD events
regulation of metabolism
c Insulin sensitivity
c Modulates hypothalamic
Variable#
High
High
High
High
Cost*
CKD, chronic kidney disease; CVD, cardiovascular disease; GIP, glucose-dependent insulinotropic peptide; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; MI, myocardial infarction; PPAR-g, peroxisome
proliferatoractivated receptor g; PROactive, Prospective Pioglitazone Clinical Trial in Macrovascular Events (30); STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (31); TZD,
thiazolidinedione; T2DM, type 2 diabetes mellitus; UKPDS, UK Prospective Diabetes Study (32,33). Cycloset trial of quick-release bromocriptine (34). *Cost is based on lowest-priced member of the class (see ref.
15). Not licensed in the U.S. Initial concerns regarding bladder cancer risk are decreasing after subsequent study. Not licensed in Europe for type 2 diabetes. #Cost is highly dependent on type/brand (analogs .
human insulins) and dosage. Adapted with permission from Inzucchi et al. (15).
- Lispro
- Aspart
- Glulisine
c Short-acting
- Human Regular
c Intermediate-acting
- Human NPH
c Basal insulin analogs
- Glargine
- Detemir
- Degludec
c Premixed (several types)
Exenatide
Exenatide extended release
Liraglutide
Albiglutide
Lixisenatide
Dulaglutide
c Canagliozin
c Dapagliozin
c Empagliozin
SGLT2 inhibitors
Cellular mechanism(s)
Activates dopaminergic
receptors
Compound(s)
Dopamine-2
agonists
Table 7.1Continued
Class
care.diabetesjournals.org
Position Statement
S45
S46
Position Statement
Figure 7.2Approach to starting and adjusting insulin in type 2 diabetes (15). FBG, fasting blood glucose; GLP-1-RA, GLP-1 receptor agonist; hypo,
hypoglycemia; mod., moderate; PPG, postprandial glucose; #, number. Adapted with permission from Inzucchi et al. (15).
Recommendations
c
care.diabetesjournals.org
Bariatric surgery is costly and has associated risks. Morbidity and mortality
rates directly related to the surgery
have decreased considerably in recent
years, with 30-day mortality rates now
0.28%, similar to those for laparoscopic
cholecystectomy (23). Outcomes vary
depending on the procedure and the
experience of the surgeon and center.
Longer-term concerns include vitamin
and mineral deciencies, osteoporosis,
and rare but often severe hypoglycemia
from insulin hypersecretion. Cohort
Position Statement
References
1. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientic review. JAMA 2003;289:22542264
2. American Diabetes Association. Intensive
Diabetes Management. 4th ed. Wolfsdorf JI, Ed.
Alexandria, VA, American Diabetes Association,
2009
3. Mooradian AD, Bernbaum M, Albert SG. Narrative review: a rational approach to starting insulin therapy. Ann Intern Med 2006;145:125134
4. Yeh H-C, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of
insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and metaanalysis. Ann Intern Med 2012;157:336347
5. Bergenstal RM, Klonoff DC, Garg SK, et al.;
ASPIRE In-Home Study Group. Threshold-based
insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224232
6. Wood JR, Miller KM, Maahs DM, et al.; T1D
Exchange Clinic Network. Most youth with type 1
diabetes in the T1D Exchange clinic registry do
not meet American Diabetes Association or International Society for Pediatric and Adolescent
Diabetes clinical guidelines. Diabetes Care 2013;
36:20352037
7. Kmietowicz Z. Insulin pumps improve control
and reduce complications in children with type
1 diabetes. BMJ 2013;347:f5154
8. Phillip M, Battelino T, Atlas E, et al. Nocturnal
glucose control with an articial pancreas at a
diabetes camp. N Engl J Med 2013;368:824833
9. Wolpert HA, Atakov-Castillo A, Smith SA,
Steil GM. Dietary fat acutely increases glucose
concentrations and insulin requirements in
patients with type 1 diabetes: implications for
carbohydrate-based bolus dose calculation and
intensive diabetes management. Diabetes Care
2013;36:810816
S47
S48
Position Statement